Morepen Labs FY25: 17 Percent EPS Growth, 40 Million Glucometers, and 600 Million Test Strips Signal Global Health Push

For Morepen Laboratories Ltd., FY25 was not only about sustaining growth. It was about setting the stage for the next phase of its expansion. The company’s investor presentation revealed clear signs of progress across all verticals including medical devices, APIs, and branded formulations.

The company reported a 17 percent year-on-year growth in earnings per share (EPS), supported by significant operational scaling. Morepen Labs has now ramped up glucometer production to 40 million units annually, with test strip capacity projected at 600 million strips each year. The installed base of glucometers stands at 14 million units, establishing its leadership in the diabetes monitoring space across India and beyond.
Morepen has announced strategic expansion plans targeting the United States and Middle East markets, reinforcing its global outlook. The company is already a recognized market leader in six active pharmaceutical ingredients (APIs), and holds the top spot in the Indian market for glucose and blood pressure monitors.

The pharmaceutical division showed 19 percent revenue growth over a three-year period, with major launches during FY25 including Sitagliptin, Apixaban, and Resmetirom. Upcoming pipeline drugs include Baricitinib and Tafamidis. These launches reflect a focus on chronic and high-growth therapeutic areas, backed by in-house development.
The company’s API export revenue now makes up 72 percent of its total API business, marking it as a consistent foreign exchange earner and a trusted global supplier. India is already one of the world’s largest producers of generic APIs, and Morepen continues to consolidate its position within this strategic category.

In distribution, Morepen operates through 5,300 distributors and reaches 343,000 retail touchpoints across India. This wide footprint is one of the reasons for its ability to scale both health devices and over-the-counter wellness products effectively.
Awards presented to the company in 2024, including ‘Best Healthcare Company’ and ‘Visionary Entrepreneur’ for its leadership, validate its positioning as a trusted innovator in the pharmaceutical and diagnostics ecosystem.
Beyond numbers, Morepen Labs’ FY25 narrative is about long-term preparation. The company is not only scaling up manufacturing. It is shaping an integrated healthcare model across diagnostics, APIs, branded pharmaceuticals, and future digital offerings.

Its medical devices segment remains a consistent growth engine. With over 14 million glucometers already installed across households and clinics, and a capacity of 600 million test strips each year, the company has become one of the most trusted names in personal diagnostics. These devices are not just tools. They are daily touchpoints for patients managing chronic conditions, especially diabetes and hypertension.
Morepen’s global strategy now points clearly toward the United States and the Middle East. These markets are actively adopting connected diagnostics and chronic care solutions. With a track record in manufacturing and exports, and more than 70 percent of its API business already coming from overseas sales, the company appears ready to take a wider step into regulated international markets.

In its pharmaceutical business, Morepen has shown that therapeutic value and affordability can move in parallel. The recent launches of Sitagliptin, Apixaban, and Resmetirom are targeted at long-term conditions such as diabetes, cardiovascular risk, and liver disease. Under development, the company has Baricitinib and Tafamidis, both aimed at complex or underserved treatment areas. These efforts reflect a broader pharmaceutical trend in India, where companies like Morepen are building their own R&D momentum rather than simply licensing generic volumes.
Digital health remains a forward-looking category. While not yet commercialised at scale, the company has indicated that digital integration with diagnostics will play a role in its roadmap. Patient data, adherence tracking, and device-led engagement are likely to become central to how its devices connect with consumers. In time, this may support new collaborations with digital platforms and telehealth providers across India and its new international markets.

With over 5,300 distribution partners and 343,000 retail points of sale, Morepen’s domestic strength continues to anchor its physical presence. Its wellness and OTC range has also benefited from this reach, reinforcing its role in preventive care, not just treatment.
Morepen’s recognition in 2024 with two national honours, Best Healthcare Company and Visionary Entrepreneur, reflects how the company is perceived within the industry. But beyond perception, it is the consistency of execution that sets it apart.
At Prittle Prattle News, our focus is always on what lies behind the press note. With editorial leadership from Smruti Bhalerao, this report views Morepen’s FY25 not just as a financial chapter, but as a strategic map. From factories to pharmacies, and from India to the global stage, Morepen Labs continues to grow in steps that are steady, evidence-backed, and aligned with the country’s healthcare future.

At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.